Sesen Bio Shares Gain On FDA Type A Meeting

 

• The FDA has granted Sesen Bio Inc's (NASDAQ: SESN) request for a Type A meeting to discuss the Chemistry, Manufacturing, and Controls (CMC) issues raised in the Complete Response Letter for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer.

• The CMC Type A Meeting has been scheduled for October 29.

• The Company is also preparing for a separate Type A meeting to discuss the recommendations specific to additional data and analyses raised in the CRL.

• The Company expects the Clinical Type A Meeting to happen later in Q4 of 2021.

https://finance.yahoo.com/news/sesen-bio-shares-gain-fda-121734463.html